Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3+LN): Eight-year follow-up analysis.
V. Moebus
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Johnson & Johnson; Roche
C. Thomssen
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Pfizer
Honoraria - Amgen; Bristol-Myers Squibb; Pfizer
Research Funding - Bristol-Myers Squibb
Other Remuneration - Amgen; Bristol-Myers Squibb; Pfizer
H. Lueck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche
W. Kuhn
No relevant relationships to disclose
A. Junker-Stein
No relevant relationships to disclose
C. M. Kurbacher
No relevant relationships to disclose
U. Nitz
Honoraria - Amgen; Roche; Sanofi
Research Funding - Amgen; Roche; Sanofi
R. Kreienberg
Honoraria - AstraZeneca; GlaxoSmithKline; Pfizer; Sanofi
M. Untch
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb
Honoraria - Amgen; Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb
C. Jackisch
Honoraria - Bristol-Myers Squibb
J. B. Huober
Consultant or Advisory Role - Bristol-Myers Squibb; Sanofi
Honoraria - Sanofi
A. Hinke
No relevant relationships to disclose
A. Du Bois
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
A. Schneeweiss
No relevant relationships to disclose